Skip to main content Skip to main navigation menu Skip to site footer

Coagulation Defects in Î’eta-Thalassemia Major Patients at Haji Adam Malik Hospital Medan



Abstract

Background: The prognosis of patients with beta-thalassemia major has improved in the last few decades, but some complications occur in thalassemia patients such as the prolongation of blood coagulation time. This study aimed to determine the difference in prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT) between beta-thalassemia major patients and healthy children, frequent and infrequent transfusion, and ferritin levels ≥ 2,500 ng/ml and < 2,500 ng/ml.

Method: This was an analytical cross-sectional study performed at Haji Adam Malik Hospital from April to August 2018 including 20 thalassemia patients and 20 healthy children. Patient data consisted of full blood count, transfusion status, coagulation parameters, serum iron, and ferritin level. The difference between coagulation parameters was analyzed using the independent t test.

Result: There was a significant difference in PT and aPTT between patients with thalassemia and healthy children (15.7 ± 1.5 vs. 13.0 ± 1.0; 42.5 ± 4.8 vs. 36.3 ± 4.8 respectively). There was a significant difference in PT between frequent and infrequent transfusion (15.41 ± 1.30 vs. 17.16 ± 2.08). There was significant difference in PT and aPTT between ferritin levels ≥ 2,500 ng/ml and < 2,500 ng/ml (18.97 ± 0.57 vs 15.93 ± 1.18; 52.92 ± 1.17 vs 42.11 ± 3.88 respectively).

Conclusion: There was a prolongation of PT and aPTT in beta-thalassemia major patients and ferritin levels ≥ 2,500 ng/ml. There was also an elongation of PT in patients who had infrequent transfusions.
Keywords: beta thalassemia blood coagulation partial thromboplastin time prothrombin time thalassemia major

References

  1. Sirachainan N, Chuansumrit A, Kadegasem P, Sasanakul W, Wongwerawattanakoon P, Mahaklan L. Normal hemostatic parameters in children and young adults with α-thalassemia diseases. Thromb Res. 2016; 146:35–42.
  2. Lanni F. Heterogenitas molekular Gena Globin-β di Indonesia. Kaitannya dengan pola penyebaran thalassemia-β serta afinitas genetik antar populasi di Indonesia. Doctoral Dissertation Medical Faculty Gajah Mada University. Yogyakarta: Gajah Mada University; 2014.
  3. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011; 118:3479– 3488.
  4. Viprakasit V, Origa R. Genetic Basis, Pathophysiology and Diagnosis. In: Cappelini MD, Cohen A, Porter J, Taher A, Viprakasit V. (Eds.) Guidelines for the Management of Transfusion Dependent Thalassemia (TDT). 3rd edition. Cyprus: Thalassemia International Federation; 2014:14–26.
  5. Abosdera MM, Almasry AE, Abdel-Moneim ES. Coagulation defects in thalassemic patients. Pediatr and Neonatol. 2017; 58: 421–424.
  6. Menteri Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Thalasemia. 2018.
  7. Chhikara A, Sharma S, Chandra J, Nangia A. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia. Indian J Pediatr. 2017; 84(1):25–30.
  8. Faraj SA. Hemostatic parameters in Thalassemia patients; a single institute experience. J Fac Med Baghdad. 2016; 58(2):132–135.
  9. Naithani R, Chandra J, Narayan S, Sharma S, Singh V. Thalassemia major--on the verge of bleeding or thrombosis?. Hematology. 2006; 11(1);57–61.
  10. World Health Organization. Joint meeting on the prevention and control of Haemoglobinopathies. Nicosia-Cyprus: World Health Organization/Thalassemia International Federation; 1994:20.
  11. Pignatti CB, Galanello R. Thalassemia and Related disorders: Quantitative Disorder of Haemoglobin Synthesis. In: Greer JP, Arber DA, Foerster J, Kluwer AFLW. (Eds.) Wintrobe’s Clinical Haematology. Philadelphia: Lippincott Williams & Wilkins; 2009:1084 – 1130.
  12. Ibrahim CP. Homeostatic derangements and lupus anticoagulant in polytransfused patients of beta-thalassemia major. Asian J Paed Pract. 1999; 3(2).
  13. Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E et al. Health related quality of life in Middle Eastern children with beta-thalassemia. BMC Blood Disord. 2012; 12: 6.
  14. Rabiner SF, Rosefeld S. Role of intravascular hemolysis and the reticuloendothelial system in the production of hypercoagulable state. J Lab Clin Med. 1963; 63:1005–1009.
  15. Andrew M, Manno M, Karpatkin M. Demostration of kallikrein-like protease activity in nonactivated plasma of patients with Cooley’s anemia. Blood. 1983; 61(2):232–7.
  16. Maiti A, Chakraborti A, Chakraborty P, Mishra S. Subclinical haemorrhagic tendency exists in patients with B-thalassemia major in early childhood. Australas Med J. 2012; 5(2): 152–155.
  17. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997; 89(3):739–61.

How to Cite

Situmorang, E., Aman, A. K., & Lubis, B. (2019). Coagulation Defects in Î’eta-Thalassemia Major Patients at Haji Adam Malik Hospital Medan. Bali Medical Journal, 8(2), 592–595. https://doi.org/10.15562/bmj.v8i2.1412
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
1

Total
2

Share

Search Panel

Eduward Situmorang
Google Scholar
Pubmed
BMJ Journal

Adi Koesoema Aman
Google Scholar
Pubmed
BMJ Journal

Bidasari Lubis
Google Scholar
Pubmed
BMJ Journal